All lobbying filings
Bravo Strategy Group
Bravo Strategy Group filed a Q3 report for Amgen on October 9, 2026, reporting $30,000 in lobbying income.
Lobbying for Amgen · biotechnology manufacturing
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 9, 2026
Income
$30,000
What the client paid this registrant for the period.
Client based in
District of Columbia
Lobbying activity
0
No itemized activity in this filing.